
|Articles|July 1, 2001
Pimecrolimus Impresses
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
3
Auricular Acupuncture for Facial Rejuvenation: Results from a Large Real-World Clinical Series
4
Off-Label Case Series: Topical Roflumilast for Mild HS
5


















